citiuspharma.comCitius Pharmaceuticals – A Specialty Pharmaceutical Company

 Home Overview Company Overview Development Strategy News & Media Leadership Board of Directors Scientific Advisory Board Careers Mino-Lok Overview Mino-Lok Medical Need Mino-Lok About CRBSIs Clinical Data Mino-Lok QIDP/Fast Track Mino-Lok Phase 3 Mino-Lok Mino-Lok Expanded Access Halo-Lido About Halo-Lido Medical Need Halo-Lido Hemorrhoids Clinical Data Mino-Wrap About Mino-Wrap Medical Need Mino-Wrap Opportunity Partnering Opportunities Investor Info Investor Overview News/Events Press Releases IR Calendar Email Alerts Company Info Profile Presentations Management Contacts FAQ Financial Information Balance Sheet Income Statement Cash Flow Financial Results Stock Data Quote Charts Historical Data SEC Filings All SEC Filings Annual Reports Quarterly Reports Section 16 Filings Governance Governance Documents/Policies Board of Directors Investor Tools Email Alerts Fact Sheet Contacts RSS News Feed Contact Citius Pharmaceuticals Pursuing a new standard of care Citius Pharmaceuticals is a specialty pharmaceutical company dedicated to the development and commercialization of therapeutic products for growing markets. Citius products offer new and expanded indications for previously-approved pharmaceutical products as a means to achieve leading market positioning. Overview Investor Relations A letter to our Shareholders, February 2021 Read More Our present...Our future. Mino-Lok ® Our Mino-Lok product is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections (CRBSIs). CRBSIs are very serious, especially in cancer patients receiving therapy through central venous catheters (CVCs), and in hemodialysis patients where venous access presents a challenge. Learn More CITI-002 CITI-002 is a topical formulation of halobetasol and lidocaine that is intended to provide anti-inflammatory and anesthetic relief to individuals suffering from hemorrhoids. In the United States, hemorrhoids affect nearly 5% of the population, with approximately 10 million patients annually reporting symptoms. Learn More Partnering Opportunities Citius is dedicated to building a successful pharmaceutical company through the development and commercialization of innovative and cost-effective products that address compelling market opportunities. We believe our 505(b)(2) expertise can assist in obtaining rapid approvals of novel products. Learn More 52 week Range - / A Message for the Investment Community The need for a product like Mino-Lok has never been greater. Please feel free to explore our site and visit our Investor Relations page for more information. For the most recent update on Company activities, please click the button below to download our latest Shareholders Letter. Citius Pharmaceuticals (NASDAQ: CTXR) Visit our Investor Relations site to stay up-to-date on our latest development and commercialization news. Investor News Citius Publishes Expert Roundtable on Catheter-Related Bacteremias Citius commissioned a roundtable of leading specialists to discuss the treatment of catheter-related bacteremias, focusing on the issue of the source of the bacteremia: the infected central venous catheter. The roundtable brought the disciplines of venous nursing care and interventional vascular management to the core specialty of Infectious Disease. The highlights of that roundtable are presented in the sponsored publication, “ Treating CLABSI: A Clinical and Economic Challenge. ” Download this Monograph Citius Pharmaceuticals RSS News Citius Pharmaceuticals, Inc. Reports Second Fiscal Quarter 2021 Financial Results and Provides General Business Update Source: Citius Pharmaceuticals, Inc. (CTXR) News Published on 2021-05-13 Citius Pharmaceuticals to Participate in Fireside Chat at the Gabelli Funds Virtual Microcap Symposium on Tuesday, May 18 Source: Citius Pharmaceuticals, Inc. (CTXR) News Published on 2021-05-11 Citius Pharmaceuticals to Present Mino-Lok® and COVID-related Respiratory Treatment Update at Benzinga Global Small Cap Conference on Thursday, May 13 Source: Citius Pharmaceuticals, Inc. (CTXR) News Published on 2021-05-04 Citius Pharmaceuticals Reports Strong Clinical Community Engagement During Mino-Lok® Phase 3 Trial-Related Webinar Source: Citius Pharmaceuticals, Inc. (CTXR) News Published on 2021-04-29 Citius Pharmaceuticals CEO Myron Holubiak Featured in Benzinga Interview Source: Citius Pharmaceuticals, Inc. (CTXR) News Published on 2021-04-22 Citius Pharmaceuticals to Highlight its Phase 3 Clinical Trial Product Mino-Lok® at Benzinga Biotech Small Cap Conference on March 25 Source: Citius Pharmaceuticals, Inc. (CTXR) News Published on 2021-03-23 Citius Pharmaceuticals to Feature Product Candidates Including Stem-Cell Therapy for COVID-19-Related Acute Respiratory Conditions at H.C. Wainwright Global Life Sciences Conference March 9-10 Source: Citius Pharmaceuticals, Inc. (CTXR) News Published on 2021-03-04 H.C. Wainwright Reiterates a Buy Rating on Citius Pharmaceuticals (CTXR) Source: Citius Pharmaceuticals, Inc. (CTXR) - In the News Published on 2021-03-01 The Daily Biotech Pulse: Aridis To Study Antibody Cocktail For Coronavirus Variants, Revance & Protalix Data Readouts Source: Citius Pharmaceuticals, Inc. (CTXR) - In the News Published on 2021-02-23 What Awaits Citius Pharma In 2021? Source: Citius Pharmaceuticals, Inc. (CTXR) - In the News Published on 2021-02-22 Citius Pharma Makes Calculated Market Moves with Phase 3 Results Looming for Potential Blockbuster Product Source: Citius Pharmaceuticals, Inc. (CTXR) - In the News Published on 2021-02-21 Citius Pharmaceuticals Announces Closing of $76.5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules Source: Citius Pharmaceuticals, Inc. (CTXR) News Published on 2021-02-19 Citius Pharmaceuticals Announces $76.5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules Source: Citius Pharmaceuticals, Inc. (CTXR) News Published on 2021-02-17 Citius Pharmaceuticals Issues Shareholder Letter with Corporate Update on Recent Achievements and Anticipated Milestones for 2021 Source: Citius Pharmaceuticals, Inc. (CTXR) News Published on 2021-02-16 Citius Pharmaceuticals Is Addressing Several Unmet Needs In The Medical Field Source: Citius Pharmaceuticals, Inc. (CTXR) - In the News Published on 2021-02-04 Citius Pharmaceuticals to Present Update on Mino-Lok and Other Therapies at the Virtual Investor Conferences Small and Microcap Showcase on February 4 Source: Citius Pharmaceuticals, Inc. (CTXR) News Published on 2021-02-02 Citius Pharmaceuticals Announces Closing of $20.0 Million Private Placement Offering Priced At-the-Market Source: Citius Pharmaceuticals, Inc. (CTXR) News Published on 2021-01-27 Citius Pharmaceuticals Announces $20.0 Million Private Placement Priced At-the-Market Source: Citius Pharmaceuticals, Inc. (CTXR) News Published on 2021-01-25 Citius Pharmaceuticals announces $20M private placement priced ATM Source: Citius Pharmaceuticals, Inc. (CTXR) - In the News Published on 2021-01-25 Citius Pharma to raise $20M through share sale Source: Citius Pharmaceuticals, Inc. (CTXR) - In the News Published on 2021-01-25 Citius Pharmaceuticals to Present Update on Proprietary Product Candidates at Two Virtual Conferences in January Source: Citius Pharmaceuticals, Inc. (CTXR) News Published on 2021-01-06 Citius Pharmaceuticals Inc. (NASDAQ:CTXR) Reports Study Results Showing Effectiveness of Mino-Lok in Eradicating Staphylococcus aureus Biofilm Source: Citius Pharmaceuticals, Inc. (CTXR) - In the News Published on 2020-12-21 Citius Holds Webinar Series on Conducting Mino-Lok Phase 3 Trial During COVID-19 Source: Citius Pharmaceuticals, Inc. (CTXR) News Published on 2020-12-15 Citius Pharmaceuticals receives FDA response to pre-IND submission for Mino-Wrap Source: Citius Pharmaceuticals, Inc. (CTXR) - In the News Published on 2020-12-10 Citius Pharmaceuticals Receives FDA Response and Guidance to Pre-IND Consultation Submission for Mino...